BCF has announced the launch of the Medison Sonovet R3 portable ultrasound scanner.
BCF says the R3 is the next evolution of the Pico from Medison which is ideal for both equine and small animal vets. It is now more compact with a robust design with enhanced image quality and improved frame rate, and even at a lower price.
Graham Howe, Partner at Stow Veterinary Surgeons in Gloucestershire has one of the new machines. He said: "We chose the Medison R3 for several reasons. The R3 is an excellent quality machine at the right price and provides excellent value for money. We wanted Doppler and the R3 provides this without breaking the bank.
"The scanner has increased our diagnostic capabilities and enabled us to diagnose increasingly subtle lesions in small animal anatomy.
"We also knew from previous experience with previous with an ultrasound scanner and digital X-ray machine that we could rely on BCF for support."
For more information visit http://www.bcftechnology.com/, or call +44 (0)1506 460023 to arrange a demonstration.
BEVA is giving its members the opportunity to participate in a free practice benchmarking survey, to help them ensure their business is being run as efficiently and profitably as possible. The results of the research will be released at BEVA Congress, 7th-10th September 2011.
The Association has worked with Hazlewoods, chartered accountants and business advisors to the veterinary profession, to develop a detailed benchmarking questionnaire for equine veterinary practices, which allows businesses to compare their practice, anonymously, with other similar practices. The report should identify areas for profit improvement, including practice structure and pricing and may also highlight other potential methods of income generation.
Mark Beaney, partner at Hazlewoods and specialist advisor to the veterinary profession, said: "This is a super opportunity for equine practices to obtain helpful, free advice on how to fine-tune their business for maximum efficiency, delivery and profit. The questionnaire should take no more than half an hour to complete and in return we will provide you with a confidential individual report, with your practice data benchmarked."
Mark will present an overall report on the equine veterinary market at BEVA Congress on Saturday 10th September. All participating practices will remain anonymous. The benchmarking survey can be downloaded from the BEVA website at: http://www.beva.org.uk/news/view/59 and must be completed by 30th June 2011.
BEVA Congress runs from 7th-10th September 2011 at the Liverpool Arena Convention Centre, Liverpool. This year BEVA will be celebrating its 50th anniversary - for further information and to register visit http://www.beva.org.uk/.
The Fédération Équestre Internationale (FEI) has added Metacam for Horses to its 'list of detection times'.
According to the manufacturer, Boehringher Ingelheim Vetmedica, Metacam (meloxicam) is the first preferential COX-2 inhibitor to be added to this list, and has stated plasma and urine detection times of 72 hours administered intravenously or orally1. This is the shortest urine detection time of the NSAIDs available for use in horses, and compares to the 168-hour (7 days) detection time for phenylbutazone stated by the FEI.
Craig Beck, equine sales and marketing manager for Boehringer Ingelheim in the UK and Ireland said: "We have been very happy to work in partnership with the FEI to provide the robust data that has supported the FEI in their analysis of Metacam. Metacam is an important addition to the FEI list, that will help vets treating competition horses. There is now a modern and proven NSAID which extends the therapeutic options available to vets."
Metacam is licensed in horses for the alleviation of inflammation and relief of pain associated with musculo-skeletal disorders or colic.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
1 Detection Time agreed with the European Horse Racing Scientific Liaison Committee (EHSLC)
Eurovet has launched Relaquine 35 mg/ml Oral Gel for Horses - a licensed acepromazine (ACP) in a gel format.
The company says Relaquine can be used to sedate horses for examination and in stressful situations that some horses find hard to deal with such as farriery, box rest, dentistry and clipping where highly-strung horses can cause problems. Relaquine is administered orally or mixed with food and is available as an adjustable syringe format containing 10 ml of gel.
Relaquine is the fourth product launch this year by Eurovet and the company says there is more in the pipeline for 2011.
Relaquine Oral Gel is expected to be available to order from veterinary wholesalers from Monday 16th May. Eurovet is also offering an introductory promotion: for further details contact Eurovet on 01223 257933.
VetSurgeon member Viki Edmondson MRCVS is taking part in a drive to help 13-year-old Octavia Woodward, who was born with spinal muscular atrophy (SMA), raise £100,000 to help The SMA Trust.
Viki, a well-known vet in the carriage driving world, will be joining Octavia on 'Octavia's Mad Marathon', a five-day, 110 mile carriage drive from Windsor to Wincanton.
Octavia will be driving her pony, Diddy, with her mother Henrietta as co-driver. Meanwhile, Viki will be driving a pair of Gelderlander horses. They'll be leaving the main ring at the Royal Windsor Horse Show with a support crew at 3:30pm on 13th May.
Viki graduated from Bristol Veterinary School in 1993. Since 2001 she has run her own equine practice plus a small animal surgery from the Newdigate, Surrey farm she shares with husband Peter. Viki has known Octavia since she was born and it was Viki who paired up Diddy with Octavia and encouraged her to progress from walking round the roads to the excitement of "off-roading". Viki will be providing support and encouragement to Octavia during the trip - of course with any veterinary help being close by.
To support Viki and Octavia, visit: http://www.justgiving.com/vikithevet
Defra has announced plans to form a new Animal Health and Welfare Board for England which will bring experts including farmers, veterinary surgeons, welfare experts and others from outside Government together with the Chief Veterinary Officer and civil servants to make direct policy recommendations on policy affecting the health and welfare of all kept animals such as farm animals, horses and pets.
According to Agriculture Minister Jim Paice, it is the first time that people affected by Government policy on animal health and welfare will make recommendations on those policies directly to Ministers.
Mr Paice said: "This is a completely new way of working. It replaces the old ways, where the people most affected by decisions were kept at arm's length from policy making on those subjects.
"This is about the Big Society not just existing in our communities, but in the heart of Government - helping to put the decisions in the hands of those who are doing the work on the ground.
"We've already seen the success of a partnership between farmers and the Government with the work that's been done on bluetongue - which has seen the disease virtually eradicated in this country."
Final decisions on animal health and welfare policy will remain in the hands of Government Ministers.
The Board will be made up of around 12 members, 5 senior Defra officials including the Chief Veterinary Officer, and 7-8 external members including the chair. The external members will have experience and knowledge of kept and farmed animals, animal and veterinary science, and animal welfare, and could be farmers, veterinarians, animal welfare experts.
The Board and its members will have to represent the views of all stakeholders so will be expected to communicate with them regularly.
The Board's responsibilities will include:
The Board will not be set up as a non departmental public body or arms length body. It will form part of the internal structure of Defra.
Commenting on the announcement, Harvey Locke, President of the British Veterinary Association, said: "The BVA is delighted that both the Advisory Group and Ministers have taken note of the veterinary profession's views in drawing up these plans.
"We said from the outset that genuine responsibility sharing has to be achieved before cost sharing can be discussed and we warned against earlier plans to separate animal health policy from animal welfare policy, as the two are intrinsically linked.
"Animal health and welfare policy issues require expert, scientific input and it will be essential that the new Board includes veterinary representation. We believe that the Board will provide the right mechanism for ensuring decisions are based on sound science.
"The new Board will also have to work closely with the three devolved administrations to ensure that animal health and welfare policies across the UK are joined up and complementary."
Alstoe Animal Health has announced that Vetergesic (buprenorphine), the UK's most commonly used injectable opiate for small animal use, is now registered for use in horses.
Developed and manufactured in the UK, Alstoe took over marketing Vetergesic 11 years ago. Two years ago the company introduced the Multi-Dose Pack, which it says allows veterinary surgeons to manage the larger liquid volumes required in horses more easily.
Alstoe says Vetergesic potentiates sedative drugs for standing sedation or routine premedication and provides profound centrally acting analgesic effects for up to nine hours. In routine procedures, this allows good recoveries and a rapid return to normal behaviour patterns.
Alstoe also says that in a thermal anti-nociceptive study carried out at Bristol University, Vetergesic showed significantly better analgesic effects than butorphanol. Field studies carried out in the UK also confirmed that when combined with a sedative, Vetergesic can provide up to 60 minutes of operating time, with smooth and quick recoveries.
John Nellis of Alstoe said: "We have invested heavily in this product and are confident that the rewards enjoyed by small animal vets will also be appreciated by their equine colleagues. We call Vetergesic 'the thoroughbred of pain management'."
Vetergesic Multidose is available for dogs, cats and horses in a 10 ml vial.
Alstoe offers an hour long explanatory seminar, which can be delivered directly to practice members. An 8 page brochure and 'pocket-sized' dose chart are also available. Further details from Alstoe on: 01347 878606 or email: info@alstoe.co.uk .
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
The results of the UK's first ever public National Equine Health Survey have quantified non-notifiable healthcare issues affecting horses, ponies, donkeys and mules in the UK.
The survey, which was pioneered by The Blue Cross animal charity and is supported by The British Equine Veterinary Association, was carried out last November following two years of pilot schemes. The intention was to find out more about endemic non-notifiable diseases that have never before been recorded in horses, ponies, donkeys and mules, such as coughs, skin diseases and lameness.
The results were announced at the National Equine Forum by Professor Josh Slater, Professor of Equine Clinical Studies at The Royal Veterinary College, who has been working with The Blue Cross on the survey.
A total of 306 sets of records were submitted from 3120 horses in mainly private ownership, with a balance of representation from competition yards, riding schools, welfare charities and studs. A broad range of syndromes and diseases were assessed including colic, sarcoids, laminitis, wounds, dental issues, eye disease, lameness and weight issues.
The results showed that lameness was the most common problem affecting horses (11% of horses surveyed) but that the foot was not the most common cause of lameness and that laminitis (3%) was less common than the 7-8% total that previous surveys had suggested.
Weight management was the next most common issue for horse owners, with 9% of horses recorded as overweight and 8% as underweight. These figures are lower than previous surveys which may be because they are based on the owner's assessment of their horse's weight which is subjective and may vary according to their perception of 'the right weight'.
Skin disease and wounds (5% and 4% respectively) posed a significant problem and colic (2%) was also a common occurrence, with a 6:1 ratio between medical and surgical cases.
The survey is breaking new ground in Europe as well as the UK. Currently Government agencies in all European countries conduct surveillance for prescribed exotic diseases such as West Nile Virus and African Horse Sickness but currently there are no large scale surveillance programmes for endemic diseases.
Professor Slater said: "The regular collection of such data holds numerous benefits to the UK equine industry. Not only does the survey provide a benchmarking facility for equine disease, welfare, standards of care and codes of practice but it will also underpin standards for yard inspection schemes. Not least it confirms the workability of an important template to monitor the serious threat of infectious and exotic disease in the future."
He added: "It's exciting to see hints in the NEHS 2010 survey that data 'straight from the horse's mouth' might challenge some established ideas. For example; the survey found that lameness was common, as you would expect, but that the foot was not the most common cause of lameness, which you might not have expected. This kind of data has never been collected before and is invaluable to the veterinary profession and wider animal welfare industry, helping to inform our future research, training and education. It will be really exciting to see the results of the larger surveys The Blue Cross are running in 2011."
Kerry Doyle, education officer at The Blue Cross said: "We are thrilled to be involved with this innovative project to enhance the future health of our horses and very grateful to all those who have participated in the survey so far. We now need even more horse owners to sign up for the next round so that we can capture as much useful data as possible."
The National Equine Health Survey is currently funded by The Blue Cross but sponsorship is being sought. It is to be conducted twice-yearly with the next census week planned for 9-15 May 2011. All keepers and owners of horses are urged to participate and details of all horse owners will remain anonymous. It's very quick and easy to complete and should only take around five minutes. To register online visit www.bluecross.org.uk/NEHS or email NEHS@bluecross.org.uk.
Ceva Animal Health has renamed Tildren, its tiludronate-based bisphosphonate infusion for the treatment of bone spavin in horses, as Equidronate.
Tiludronate has been used to treat bone spavin and navicular disease in Europe for many years and was licensed for bone spavin in the UK in 2008. Ceva says trials published last year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints and is considered to be one of the most common forms of hindlimb lameness in the horse. Horses with bone spavin experience abnormal bone remodeling changes. According to the company, Equidronate helps to modulate the osteoclasts to help prevent excessive bone removal and give the osteoblasts a chance to catch up. This in combination with adjusting levels of exercise helps to harmonise the bone adaptation needed for the horse to perform its athletic duties.
In the trials one in four horses showed marked improvement; two in four showed improvement, which, when combined with other treatment, enabled the horse to resume former levels of activity and one in four horses showed no response.
Ceva Animal Health has produced a range of explanatory leaflets for horse owners on bone spavin, navicular disease and sacroiliac disease, as well as a helpful booklet detailing the discharge procedures for horses that have been treated with Equidronate.
For free copies and for further product information contact your Ceva sales representative, ring Ceva on 01494 781510 or visit the website at http://www.ceva.uk.com/
Ledston Equine Clinic in West Yorkshire has announced the launch of the Ledston Education Centre, which will provide training for veterinary surgeons, fire and rescue personnel, and horse owners.
The Ledston Education Centre will continue the clinic's "Tuesday evening lecture" series, and training for fire and rescue personnel will be carried out under the Safer Horse Rescues Initiative.
WebLeC is a new development through which the Centre says it will deliver online training for equine veterinary surgeons and students, and high quality equine healthcare information to horse owners across the UK. WebLeC uses web conferencing software to deliver live, interactive lectures and discussion forums to people in the comfort of their own homes.
Forthcoming WebLeC CPD meetings:
Wed 9th March 2011 at 7.30pm: "Strangles and the practical management of infectious disease outbreaks in horses"Prof. Josh Slater, BVM&S PhD DipECEIM MRCVS Professor of Clinical Equine Studies, Royal Veterinary College.Kindly sponsored by Intervet Schering-PloughFee: This meeting is FREE of charge for first 100 applicants
Thu 17th March 2011 at 7.30pm: "Insulin Resistance, Equine Metabolic Syndrome, & Equine Cushings (PPID) - a practical approach to diagnosis and management"Dr. Cathy McGowan, BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS Director of Equine Professional Studies, University of LiverpoolKindly sponsored by Boehringer IngelheimFee: This meeting is FREE of charge for first 100 applicants
Further information can be found at: http://www.ledstonequine.co.uk/weblec_lectures.html. The Ledston Education Centre says details of how to register will be available on the website shortly.
Boehringer Ingelheim Vetmedica has launched a series of information sheets written by veterinary surgeons, nutritionists and leading riders to support its muscle building supplement for horses, Equitop Myoplast Power Pearls.
Available to download as PDFs from its website - http://www.equitop-myoplast.co.uk - this resource for horse owners covers a range of feeding topics including training the young showjumper and feeding the performance horse, older horses and horses during periods of rest and recuperation.
New video and written testimonials from performance riders and veterinary surgeons are now on the website, which also offers owners advice on healthy lean muscle growth and the benefits of Equitop Myoplast. Olympic dressage rider, Emile Faurie, international showjumpers, Ellen Whitaker and Scott Brash, and show horse producer, Katie Jerram, all endorse the product.
A client leaflet has also been launched featuring the testimonials and providing owners with information on Equitop Myoplast and an online offer of £15 off their first purchase of the supplement by downloading a voucher from the website.
Boehringer says Equitop Myoplast is packed with 18 key amino acids and is scientifically designed to support lean muscle growth, not bulk. The company says the supplement is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
Boehringer Ingelheim Vetmedica has launched Buscopan 20mg/ml injection, an antispasmodic treatment for use in cases of equine colic, and an aid to the symptomatic treatment of calf scour.
A sister product to Buscopan Compositum which contains both an antispasmodic and a non-steroidal component, Buscopan 20 contains only the antispasmodic component - hyoscine butylbromide.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Our customers have been telling us for some time that they would really welcome a Buscopan formulation without an NSAID for use in horses and cattle. I'm pleased to say that it's finally here and I'm sure that Buscopan 20 will be a very welcome addition to the armoury of both equine and cattle practitioners."
Buscopan 20 is supplied in a 50ml multi-dose bottle, and is available in veterinary wholesalers now.
For further information, please call 01344 746959.
DG Sanco, the EU Directorate General for Health and Consumers, has launched a worldwide photo competition to mark World Vet Year: 'Vets in your daily life'
Entries need to be photos of a vet (or vets) at work or in any situation which shows the diverse nature of the job. Five winners will win 1000 Euros worth of photographic equipment. The overall winner will win an additional 2000 Euros worth of photographic equipment. All winners will also be given travel and accommodation for the awards ceremonies in Paris and Brussels.
Anyone (except for employees of the European Institutions, and their families) can enter the competition, which closes on 31st March 2011. More details can be found at: www.vetsinyourdailylife.org.
Here's the promotional video for the competition:
Grahame Gardner has introduced the M559, a classically styled tunic, stocked for the first time in bottle green.
The company says that although it has sold numerous ladies tunics in bottle green, this is the first time it has stocked a male tunic in the characteristic veterinary colour.
The M559 incorporates side fastening with the option of contrasting epaulettes, alongside practical pockets and side slits.
Simon Ward, Sales Director said: "We are delighted to introduce this new garment to the veterinary market. We are continually reviewing our range in response to customer comments, and felt it was time we stocked a bottle green option, specifically for male members of the veterinary team."
Stocked in sizes from 34" to 50" (chest), the M559 is just one of several new styles introduced in Grahame Gardner's latest brochure. The company is also launching a new men's scrub tunic. The SS3295 has a v style neck, complemented by the v-detail on the sleeves, and contrasting trim available on the neck, sleeve and pocket. Also stocked in bottle green, the company says this tunic is aimed at veterinary professionals who prefer a more relaxed approach to uniforms.
To explore Grahame Gardner's collection please take a look at http://www.grahamegardner.co.uk/, or call 0116 255 6326 to order a copy of their new brochure.
The Horserace Betting Levy Board (HBLB) has launched an online version of the Codes of Practice on equine diseases, ready for the 2011 Thoroughbred breeding season.
The website, codes.hblb.org.uk is a replica of the 2011 booklet, but with an easy to use navigator and built-in text search.
The 2011 online Codes of Practice set out minimum recommendations for the prevention and control of disease. Applying to all breeds of horse and pony, and to both natural mating and AI, the Codes cover:
The increasing mobility of horses creates a subsequent increased risk of spreading infectious disease. In recent years, most countries with active horse populations have seen incidents of these diseases, including in Britain the notifiable diseases of CEM, EIA and EVA.
Any of these diseases can have serious consequences for horse and pony breeding, compromising welfare, disrupting breeding activity and causing economic loss and distress.
Professor Willie Donachie, Chairman of the HBLB's Veterinary Advisory Committee said: "We recognise the changing ways in which vets, studs and individual breeder's access information. The new online version of the Codes is designed to reflect this and ensure that the Codes of Practice, a vital resource, are available where and when they are needed."
Merial is offering four free tubes of Eqvalan Duo to practices that buy 20 tubes in February and March. In addition, to further boost the targeted worming message, Merial will supply 20 free worm egg count vouchers worth £10 each.
Eqvalan Product Manager Claire Edmunds said: "Last year's campaign was so well received by both practices and clients that we have decided to run it again and are hoping for even better results!
"The personalised online planner, worm egg count offer and new eye-catching point of sale all help you to engage your clients in a targeted worming strategy.
For those practices with their own, in-house worm egg count testing facilities, Merial is also offering promotional support to help encourage increased uptake and client buy-in. The campaign forms part of Merial's promotion and education strategy for 2011, which includes extensive VN SQP CPD training opportunities.
To find out more contact your local Area Manager or call the Merial Customer Support Centre on 0845 601 4236
Equine vets and farriers in South Wales who need horses x-rayed can now use a new mobile service offered by Equiray. Operating 24 hours a day, 7 days a week, Equiray's technicians travel to the site to take digital x-rays, using state-of-the-art imaging equipment.
At the heart of Equiray's service is the Uno Equine portable digital x-ray system; the only system in the world that has a capture screen built into the generator. All images taken can be viewed within minutes and decisions made there and then regarding further tests. The x-ray images are emailed to the veterinary surgeon immediately, or supplied to the practice on a CD or memory stick. They are also stored securely by Equiray for a 3 month period.
For farriers, the image can be displayed on screen so they can see the internal bone structures encapsulated within the hoof before they start remedial work, and then another x-ray taken after the work has been completed. Both images can be viewed together for comparison.
Equiray says its service means practices don't have to buy and maintain costly equipment, nor send a practice technician to attend with the vet, as all Equiray technicians are highly skilled in equine imaging.
Equiray currently operates mainly in South Wales but with requests coming from other areas of the country, the company says its technicians are travelling to x-ray several horses in a particular area, over a 2 day period. Remedial farriers requiring monthly x-rays of certain horses are also using the service and plans to extend the service nationally are in progress.
For more information, visit www.equiray.co.uk/
Vets attending the first veterinary-led European Equine Transport Forum, held in Brussels last November, have agreed that the profession needs to take a leading role to help enforce the current regulation governing the long-distance transport of horses, in order for equine welfare standards to be improved.
In support, the British Equine Veterinary Association (BEVA) Trust has announced the introduction of the BEVA Trust Equine Transport Enforcement Award of €1000, to be given annually to the individual or group doing the most to improve enforcement of the current transport regulation.
The Forum was initiated by BEVA President Madeleine Campbell in conjunction with the Federation of Veterinarians of Europe (FVE) and is sponsored by the BEVA Trust and World Horse Welfare. It attracted representatives from 38 nations; including a strong turnout from Eastern Europe where horses sourced for slaughter often start their journeys and Italy which is the end destination for the majority of these horses.
The plight of horses sourced for slaughter was the main focus for discussion and the key issues raised were:
Delegates also examined the long-term need to change the attitude of Italian consumers, raising awareness of the current welfare issues related to their preference for fresh meat, labelled as Italian produce. In addition they discussed the impact on equine welfare of increased profits in sourcing horses in Eastern Europe and then transporting them long distances for slaughter.
Dr Madeleine Campbell said: "The atmosphere throughout the day was one of collaboration and determination to succeed. Proper enforcement of the current regulation is the key to welfare improvements, as is the need for a system of best practice to drive a change in cultural attitudes about how horse meat is produced. A process of education is necessary so that consumers understand the welfare issues associated with long-distance transport and start demanding accurate information about where the meat which they are buying originally came from, and how far the horses travelled to slaughter. We are all in agreement that vets have a pivotal role to play in both education and enforcement, and that they want to play it."
Nominations for the annual BEVA Trust Equine Transport Enforcement Award are open and can be made via the FVE and the BEVA Trust. The award will be judged by the FVE Working Group on Transport, and will be awarded for the first time in November 2011. The programme, abstracts and presentations from the Forum can be found at: http://www.fve.org/events/index.html#conferences
Novartis Animal Health has announced that it will begin marketing and distributing Adequan Equine in the UK from January 2011.
According to the company, Adequan Equine offers equine veterinarians a proven intramuscular treatment option for equine degenerative joint disease, also known as non-infectious arthritis or osteoarthritis. The product is licensed in the UK for the treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital flexor tendonitis. This is a critical treatment area since equine degenerative joint disease is estimated to cause up to one-third of all equine lameness cases1. It most commonly affects the hocks and coffin joints with the most severe effects on the high-motion knee and fetlock joints.
Esther Rawlinson MRCVS, Global Technical Services Manager for the Novartis Animal Health Companion Animal Business in the Therapeutics & Equine areas said: "Adequan Equine is a leading joint treatment for horses and is widely used by veterinarians in the equine sport industry. Adequan Equine reduces pain and lameness in horses while at the same time stimulating cartilage repair.
Adequan Equine 100mg/ml solution contains polysulphated glycosaminoglycan for intramuscular injection. It is a chondroprotective, meaning it inhibits the breakdown of cartilage in diseased joints while at the same time supporting its repair.
Adequan Equine works by blocking the destructive enzymes formed in the joint as a result of inflammation while stimulating the production of hyaluronic acid to restore the synovial fluid, and the synthesis of cartilage building compounds.
Dechra Pharmaceuticals PLC has announced that it has acquired the entire issued share capital of Genitrix Limited ("Genitrix") from its owner managers for an initial cash consideration of £5.4 million, with a further £0.8 million being payable upon achievement of specific milestones.
Dechra says the acquisition of Genitrix is consistent with its strategy to grow its international veterinary pharmaceutical business. In the year ended 31 March 2010, Genitrix achieved revenues of £2.4 million.
Ian Page, Chief Executive of Dechra, said: "Genitrix range of equine and companion animal products enhances and complements our UK product portfolio. Furthermore the recently approved canine epilepsy product, Libromide, provides future growth opportunities through potential mutual recognition in Europe. The acquisition is expected to be earnings enhancing in the first full year following ownership."
Pfizer Animal Health is advising vets and horse owners to be on guard against the threat of West Nile Virus (WNV) in the UK, following a spate of outbreaks of the disease in several European countries this year.
West Nile Virus has recently made headline news because of a human outbreak in Greece which resulted in a number of deaths. Outbreaks have also occurred in Russia, Romania and Italy during 2010. West Nile Fever is a viral disease transmitted by mosquitoes, which carry the virus after biting infected birds. Primarily occurring between July and October, in line with typical peak activity of mosquitoes, it can have serious consequences on human and equine health, with severe cases resulting in fatal neurological disease.
There is no cure, though supportive treatment can aid recovery. However if the disease progresses to a state where the animal is not able to stand up, their chance of survival is considered low. Prevention of infection is difficult, but any steps that reduce mosquito numbers or the likelihood of horses and people being bitten may help to reduce the risk in areas where the disease is present. However, the only way to reduce the risk of an individual horse developing disease due to WNV is through vaccination.
Ben Gaskell, Pfizer's equine veterinary advisor said: "West Nile Virus may well become a very real threat to both horses and humans in Northern Europe. It is important for vets, horse owners and infectious disease experts to work together to mitigate its impact in the event of the virus becoming endemic across Europe. The rapid spread of the disease across North America is an illustration of what could potentially happen in Europe and it is important to remember there is no curative treatment - the only way to prevent clinical disease in horses is by vaccination."
Pfizer Animal Health supports the PrEquID (Prevention of Equine Infectious Disease) group, which consists of internationally recognised equine and infectious disease experts. The group was formed to develop guidelines on the prevention and control of a number of equine infectious diseases, on a global basis.
Klaus Osterrieder, Professor and Chair in the Institut für Virologie in the Veterinärfakultät at Freie Universität Berlin, Germany and a member of the PrEquID group advises: "Horse owners should ask their veterinarian for advice on appropriate prevention measures. Experience has shown that adopting a prudent prevention strategy can be a very effective way of managing this devastating disease."
Further information on WNV is available at www.westnile.eu.
To mark today's European Antibiotic Awareness Day 2010, the British Veterinary Association is warning veterinary surgeons in the UK that failure to use antimicrobials responsibly could result in their use being restricted.
The BVA promotes the responsible use of antimicrobials and last year published a poster and guidance for vets: 'Responsible use of antimicrobials in veterinary practice: the 8-point plan'. According to the association, the poster received very positive feedback from across the UK and from the Federation of Veterinarians of Europe (FVE).
Concerns regarding resistance to antimicrobials and antibiotics span both the human and animal medicine fields and in 2008 the Chief Medical Officer called for a ban on the use of certain types of antibiotics in animals in order to protect their activity in humans.
Furthermore some EU Member States already restrict the availability of antimicrobials to veterinary surgeons and adopt a strict formulary approach to the medicines that they can prescribe. The BVA says it is concerned that this trend will reach the UK and the freedom of vets to prescribe according to their clinical judgement will be restricted.
Harvey Locke, President of the BVA, said: "Antimicrobial resistance is an enormous problem for both human and animal health. As veterinary surgeons we have a duty to use these medicines responsibly for the good of animal health and welfare as well as public health.
"The BVA's poster on responsible use should be displayed in veterinary practices across the UK as a constant reminder, and I would urge all vets to refer to it.
"Failure to heed the message of responsible use could result in vets losing the right to prescribe certain medicines, which could have a significant impact on animal health and welfare.
"On Antibiotic Awareness Day our message to vets is clear: use them responsibly or lose them."
Ceva Animal Health has produced a new booklet explaining the discharge procedures for horses that have been treated with Equidronate (formerly called Tildren), a bisphosphonate infusion used for the treatment of bone spavin.
Ceva says the new booklet is designed for vets to give their clients to help convey the most effective post-treatment management protocol. It explains what Equidronate is, how it works and how it is administered. It goes on to cover how owners can help to monitor progress once exercise has commenced, by completing the specially created assessment forms contained within the booklet every couple of weeks.
According to the company, trials published earlier this year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Copies of the new leaflet are available free of charge from your Ceva sales representative. Leaflets on understanding bone spavin, understanding navicular disease and understanding sacroiliac disease are also available.
Horiba Medical - UK has launched MLT-Diode Laser Systems, specifically designed for veterinary use, as part of its portfolio of animal healthcare products.
According to the company, the MLT-Diode Lasers are highly versatile and can be used in a variety of veterinary applications including surgery, endoscopy, dentistry and irradiation.
The two models, the MLT-Diode Laser Classic and Premium, both feature touch screen controls and are adaptable to each users individual preferences. Designed with small animal practices in mind, the Classic has a performance out-put of 8 watts whilst the more powerful Premium model is for equine medicine with an output of 15 watts. The system is mounted on a mobile cart with a protection case, allowing the whole system to be moved between treatment rooms and enabling near patient application.
Horiba Medical will be exhibiting the MLT-Diode Laser Systems at the London Vet Show at Olympia, 22nd to 23rd October 2010, on Stand M4.